A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.
Katrien Berns,Hugo M. Horlings,Bryan T. Hennessy,Mandy Madiredjo,E. Marielle Hijmans,Karin Beelen,Sabine C. Linn,Ana M. Gonzalez-Angulo,Katherine Stemke-Hale,Michael Hauptmann,Roderick L. Beijersbergen,Gordon B. Mills,Marc J. van de Vijver,René Bernards +13 more
1.6K
TL;DR: Assessment of PI3K pathway activation may provide a biomarker to identify patients unlikely to respond to trastuzumab-based therapy, and the combined analysis of PTEN and PIK3CA identified twice as many patients at increased risk for progression compared to PTEN alone.
read more
About: This article is published in Cancer Cell. The article was published on 16 Oct 2007. and is currently open access. The article focuses on the topics: Trastuzumab & Breast cancer.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Ridaforolimus improves the anti-tumor activity of dual HER2 blockade in uterine serous carcinoma in vivo models with HER2 gene amplification and PIK3CA mutation.
Silvia F. Hernandez,Sarah Chisholm,Darrell R. Borger,Rosemary Foster,Bo R. Rueda,Whitfield B. Growdon +5 more
TL;DR: Pilot data suggest that PIK3CA gene mutation may be an effective biomarker for selecting those HER2 over-expressing USC tumors most likely to benefit from mTOR inhibition.
4
•Dissertation
Biomarqueurs prédictifs de la réponse aux traitements par thérapies ciblées dans le cancer du sein
Maëva Lion
- 16 Dec 2015
TL;DR: Notre travail avait pour objectifs d'identifier de nouveaux biomarqueurs de reponse a l'association trastuzumab-everolimus chez des patientes presentant un cancer du sein precoce traitees en preoperatoire.
4
Recent Developments in Targeting Breast Cancer Stem Cells
Yolanda Sanchez,Angel G. Martin +1 more
- 01 Jan 2011
TL;DR: This work discusses the recent observation that links the tumor suppressor p53 and induced pluripotency reprogramming which has lead to the speculation that cancer stem cells may arise through an altered reprograming-like mechanism.
4
Identifying predictive markers of response and resistance to potent multi-agent her2-targeted therapy
Carmine De Angelis
- 10 Apr 2017
TL;DR: PI3K pathway hyperactivation is associated with resistance to lapatinib and trastuzumab without chemotherapy, and future studies should investigate targeting PI3K/Akt/mTOR, in addition to HER2, in patients with HER2-positive tumors and evidence of aberrant downstream PI3k pathway activation.
4
Novel Therapies to Overcome HER2 Therapy Resistance in Breast Cancer
Rita Nahta
- 01 Jan 2019
TL;DR: This chapter will provide a detailed overview of the mechanisms of resistance in HER2-positive breast cancers and therapeutic strategies for patients who have developed progressive disease while being treated with HER2 antibody therapy.
4
References
edgeR: a Bioconductor package for differential expression analysis of digital gene expression data.
TL;DR: EdgeR as mentioned in this paper is a Bioconductor software package for examining differential expression of replicated count data, which uses an overdispersed Poisson model to account for both biological and technical variability and empirical Bayes methods are used to moderate the degree of overdispersion across transcripts, improving the reliability of inference.
39.8K
MicroRNAs: Genomics, Biogenesis, Mechanism, and Function
TL;DR: Although they escaped notice until relatively recently, miRNAs comprise one of the more abundant classes of gene regulatory molecules in multicellular organisms and likely influence the output of many protein-coding genes.
36.3K
MicroRNAs: Target Recognition and Regulatory Functions
TL;DR: The current understanding of miRNA target recognition in animals is outlined and the widespread impact of miRNAs on both the expression and evolution of protein-coding genes is discussed.
20.3K
Molecular portraits of human breast tumours
Charles M. Perou,Therese Sørlie,Michael B. Eisen,Matt van de Rijn,Stefanie S. Jeffrey,Christian A. Rees,Jonathan R. Pollack,Douglas T. Ross,Hilde Johnsen,Lars A. Akslen,Øystein Fluge,Alexander Pergamenschikov,Cheryl A. Williams,Shirley Zhu,Per Eystein Lønning,Anne Lise Børresen-Dale,Patrick O. Brown,David Botstein +17 more
TL;DR: Variation in gene expression patterns in a set of 65 surgical specimens of human breast tumours from 42 different individuals were characterized using complementary DNA microarrays representing 8,102 human genes, providing a distinctive molecular portrait of each tumour.
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
Dennis J. Slamon,Brian Leyland-Jones,Steven Shak,Hank Fuchs,Virginia E. Paton,Alex Bajamonde,Thomas Fleming,Wolfgang Eiermann,Janet M. Wolter,Mark D. Pegram,José Baselga,Larry Norton +11 more
TL;DR: The addition of trastuzumab to chemotherapy was associated with a longer time to disease progression, a higher rate of objective response, a longer duration of response, and a lower rate of death at 1 year.
12.4K
Related Papers (5)
Edward H. Romond,Edith A. Perez,John Bryant,Vera J. Suman,Charles E. Geyer,Nancy E. Davidson,Elizabeth Tan-Chiu,Silvana Martino,Soonmyung Paik,Peter A. Kaufman,Sandra M. Swain,Thomas M. Pisansky,Louis Fehrenbacher,Leila A. Kutteh,Victor G. Vogel,Daniel W. Visscher,Greg Yothers,Robert B. Jenkins,Ann M. Brown,S. R. Dakhil,Eleftherios P. Mamounas,Wilma L. Lingle,Pamela M. Klein,James N. Ingle,Norman Wolmark +24 more